0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover257.04%IV5.93%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.5940Delta0.2545Gamma4.29Leverage Ratio-0.0131Theta0.0005Rho2.55Eff Leverage0.0023Vega
MEI Pharma Stock Discussion
“On October 22, 2024 (the “Closing Date”), MEI Pharma, Inc., a Delaware corporation (the “Company”), and Aardvark Therapeutics, Inc., a Delaware corporation (the “Purchaser”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), pursuant to which the Company sold its rights, title and interest in and to certain assets related to ME-...
Wohooo
NEWS
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma, Inc. reports positive results from the ongoing Phase 1b study of ME-344 in combination with bevacizumab for relapsed metastatic colorectal cancer. 25% of patients had no disease progression at Week 16, exceeding the threshold to add more patients. The combination was well-tolerated, leading to the...
$Gossamer Bio (GOSS.US)$ $Starry Group (STRY.US)$ $Helbiz (HLBZ.US)$ $MEI Pharma (MEIP.US)$ $Digital Brands Group (DBGI.US)$ $Cosmos Health (COSM.US)$ $COMSovereign (COMS.US)$ $Mirati Therapeutics (MRTX.US)$ $United Parcel Service (UPS.US)$ $Sumo Logic (SUMO.US)$
No comment yet